Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMN-201 Delivery in Ostomy Patients
NCT04893239Phase 1Completed
- Sponsor
- Lumen Bioscience
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Microbiome Therapeutics, Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMN-201 in Clostridioides difficile infection (CDI) (4 cohorts), sponsored by Lumen Bioscience. Primary endpoint: Number of Participants With Presence of Capsules and/or Transit Markers in Ostomy Fluid by Visual Observation. Started Aug 2021; status: completed.
02
Drugs
LMN-201
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04893239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893239.